Apimeds Pharmaceuticals US, Inc. develops non-opioid, biologic-based therapies for pain management as a clinical-stage biopharmaceutical company. Company news centers on Apitox, also referenced as LT-100, a pure honeybee venom biologic candidate for signs and symptoms of osteoarthritis, with historical approval in South Korea under the Apitoxin name.
Recurring updates also cover U.S. regulatory interactions, clinical-development planning, material agreements, shareholder voting and governance matters, capital-structure disclosures, and operating results. Apimeds has also announced ai² Futures Lab collaborations tied to evaluation of early-stage pharmaceutical assets and biopharma business development projects.
Apimeds Pharmaceuticals US (APUS) subsidiary MindWave Innovations will make NILA available for trading on Pionex starting October 14, 2026. Trading is scheduled for 6 a.m. Eastern Time through the NILA/USDT pair, subject to platform eligibility, account verification and jurisdictional restrictions.
NILA currently exists as a BEP-20 token and is planned to move to MindChain once that network is live. MindWave has signed agreements to build AQUAEChain, FlashChain and AssureChain on MindChain. A migration portal and tracking tools are planned, subject to legal, regulatory, technical and compliance requirements.
Apimeds Pharmaceuticals US (NYSE American: APUS) subsidiary MindWave signed three client agreements to build and operate networks on its MindChain infrastructure. Signed between September 24 and October 4, 2026, the agreements cover climate finance, sports media and insurance, with compensation through fees or equity plus credit or token allocations.
The 12-month AQUAE agreement provides service fees and 20% of ALCI Credits issued and outstanding. The 12-month Flash Sports & Media agreement provides FLZH common shares and 20% of FLASH TOKEN's total supply. The two-year BlockAssure agreement provides quarterly development fees and 20% of AssureCoin's total supply.
Separately, Apimeds disclosed that its fiscal 2025 audit report expressed substantial doubt about its ability to continue as a going concern. The disclosure does not change or amend its fiscal 2025 filings.
Apimeds Pharmaceuticals US (APUS) subsidiary MindWave Innovations signed a two-year agreement with BlockAssure to build, deploy and operate AssureChain.
Effective October 4, 2026, the agreement makes MindWave the exclusive blockchain provider for the insurance and reinsurance network. MindWave will earn development fees in quarterly installments; later operating and maintenance fees remain to be agreed. It will receive 20% of AssureCoin's total supply when the planned token is created, fully vested on delivery, with anti-dilution protection during the term and for two years afterward. Development is planned over four quarters, with module acceptance testing by BlockAssure. MindWave provides technology; BlockAssure handles underwriting, claims decisions and licensing.
Apimeds Pharmaceuticals US (APUS) subsidiary MindWave Innovations signed a 12-month agreement with Flash Sports & Media Holdings to build and operate FlashChain.
MindWave will deploy a dedicated subnet on MindChain and provide development and technical services for ticketing and media records. Its consideration includes FLZH common shares and an allocation equal to 20% of FLASH TOKEN's total supply. The agreement also provides for an annual maintenance fee equal to 50% of applicable contract consideration. FLZH will own FlashChain and hold a perpetual license to two software components. Technical specifications and delivery timelines remain to be set in a statement of work, and each deliverable is subject to FLZH acceptance testing.
Apimeds Pharmaceuticals US (APUS) subsidiary MindWave signed a 12-month technology services agreement with AQUAE Holdings to build and operate AQUAEChain.
Effective September 14, 2026, the agreement calls for MindWave to develop, deploy and host the ALCI Credits platform, then provide technical support once it is live. MindWave will earn contracted software development and technology service fees. It will also receive an allocation equal to 20% of the total ALCI Credits issued and outstanding on AQUAEChain, calculated at the end of each quarter using the MindChain issuance ledger. AQUAE will lead the credit methodology and market development. The parties expect a further five-year services arrangement after the initial term, subject to mutual agreement and definitive documentation.
MindWave Innovations (NYSE American: APUS), a subsidiary of Apimeds Pharmaceuticals US, announced that its NILA token is now available to eligible U.S. users on Webot, a licensed U.S. cryptocurrency exchange registered as an MSB with FinCEN and holding Money Transmitter Licenses in 48 states (NMLS #2284360).
The listing provides U.S. access to NILA ahead of its planned migration to MindChain, an insured Layer 2 network on Ethereum expected to launch in October 2026, subject to completion of legal, regulatory, technical, and compliance requirements. A test network is planned for August–September 2026, with a migration portal and token tools expected at MindChain go‑live.
Apimeds Pharmaceuticals US (NYSE American: APUS), via wholly owned subsidiary MindWave Innovations, announced MindChain, described as the world's first fully insured, EVM-compatible Layer 2 blockchain, scheduled for mainnet launch in October 2026 with Ethereum as the settlement and data availability layer.
The company also disclosed that its NILA token will become available to U.S. users on Webot, a licensed U.S. crypto exchange with Money Transmitter Licenses in 48 states, starting August 3, 2026, ahead of NILA becoming MindChain’s native gas and staking token.
Apimeds Pharmaceuticals US (NYSE American: APUS) reached a settlement with Inscobee parties to resolve disputes from its Dec 1, 2025 merger. The agreement clears the way to complete merger transactions, close a $100 million PIPE financing, resume NYSE American trading on May 5, 2026, and advance the Apitox program via newly formed Lōkahi Therapeutics.
The deal assigns Apitox assets to Lōkahi, delivers $4.0 million to APUS, transfers a $2.2 million Prevail CRO credit facility, allocates 10% of financing net proceeds to a Newco, and directs a 51% Lōkahi distribution as specified by Erik Emerson.
Apimeds Pharmaceuticals US (NYSE:APUS) stockholders led by Inscobee and Apimeds Korea delivered a written consent on March 20, 2026 removing four directors and appointing three new directors, reducing the board to three and naming Youngjik Cho as CEO effective immediately.
The majority holders claim the Written Consent is valid; MindWave issued a separate release disputing that validity and threatening litigation. The majority cites concerns about MindWave's alleged 1000 bitcoin ownership in the prior Merger.
Summary not available.